Antimalarial drugs hydroxychloroquine and chloroquine began to write in 46 times more likely after the President of the United States Donald trump about their effectiveness in the treatment of coronavirus, according to the American newspaper New York Times.
According to the newspaper, the demand for anti-malarial medicines have increased to 46 times the next day after the press conference trump March 19, during which the US President first announced the effectiveness of the drugs. To prove the beneficial effect of hydroxychloroquine and chloroquine is not currently managed. However, according to the publication, about 32 thousand prescriptions for antimalarial drugs were prescribed by rheumatologists, cardiologists, dermatologists, psychiatrists and orthopedists. According to the New York Times, in April, the frequency assignments of these medications has declined, but still exceeded the norm by six times.
The US President Donald trump has repeatedly commented positively about the antimalarial drugs chloroquine and hydroxychloroquine for the treatment of COVID-19 and was reported encouraging results of treatment. Experts have warned that the President’s statements about drugs that were not officially approved for the treatment of COVID-19, premature and dangerous. Specialists said the risk of taking drugs because of possible side effects.
Earlier Wednesday, the medical portal medRxiv Preprint published a study according to which patients with coronavirus in medical centers in the United States who had taken hydroxychloroquine had higher mortality rates than those who don’t.
The study involved 368 patients who until April 11 was admitted to the medical centres subordinated to the Ministry of veterans Affairs of the United States. Of these, 97 people took hydroxychloroquine, mortality in this group was 27.8 per cent, from 158 patients who did not take the drug, this indicator was equal to 11.4%. Another 113 patients received hydroxychloroquine in combination with the antibiotic, azithromycin, in this group the mortality rate was 22.1%. The study was conducted by a team of scientists from South Carolina and Virginia.
Relevant data on the situation of COVID-19 in Russia and the world presented on the portal stopmanager.of the Russian Federation.
